Holen Sie sich die Stockscreener-App
56.80
1.03%
0.58
Handel nachbörslich:
57.09
0.29
+0.51%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.22
Offen:
$56.18
24-Stunden-Volumen:
10.30M
Relative Volume:
0.99
Marktkapitalisierung:
$114.75B
Einnahmen:
$47.44B
Nettoeinkommen (Verlust:
$-7.26B
KGV:
14.42
EPS:
3.94
Netto-Cashflow:
$13.80B
1W Leistung:
-5.05%
1M Leistung:
+6.73%
6M Leistung:
+29.00%
1J Leistung:
+11.72%
1-Tages-Spanne:
$55.84
$56.84
1-Wochen-Bereich:
$55.82
$60.62
52-Wochen-Spanne:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BMY | 56.80 | 114.75B | 47.44B | -7.26B | 13.80B | 3.94 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Swiss National Bank - MarketBeat
Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Justice on the Move: The Impact of Bristol-Myers Squibb on FLSA Forum-Shopping - The National Law Review
9,269 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Sargent Investment Group LLC - MarketBeat
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Stake Lessened by KBC Group NV - MarketBeat
Plato Investment Management Ltd Purchases 13,447 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024 - Indian Pharma Post
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
ICICI Prudential Asset Management Co Ltd Sells 38,500 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now? - Insider Monkey
Oppenheimer & Co. Inc. Raises Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink - FiercePharma
Pinnacle Financial Partners Inc Acquires 272,439 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mengis Capital Management Inc. Has $3.37 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Aigen Investment Management LP Sells 102,823 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Equities Analysts Issue Forecasts for BMY Q4 Earnings - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Upgraded by Leerink Partnrs to "Strong-Buy" Rating - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00 at Citigroup - MarketBeat
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Bristol-Myers Squibb's $14 Billion PotentialAnalyst Upgrades Stock - Benzinga
BMO Capital Markets Boosts Bristol-Myers Squibb (NYSE:BMY) Price Target to $61.00 - MarketBeat
AbbVie’s loss is Bristol Myers Squibb’s gainanalyst - Proactive Investors USA
American Assets Inc. Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers gets stock price target boost, rating held on Cobenfy outlook - Investing.com
Morgan Stanley Raises Bristol-Myers Squibb (NYSE:BMY) Price Target to $39.00 - MarketBeat
Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch
Bristol-Myers upgraded at Leerink after AbbVie setback - MSN
Bristol-Myers Squibb (NYSE:BMY) Upgraded at Leerink Partners - MarketBeat
Bristol-Myers stock upgraded at Leerink (BMY:NYSE) - Seeking Alpha
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):